BioSpecifics Technologies Corp

BioSpecifics Technologies — Investor Presentation (September 2017)

27 slides from BioSpecifics Technologies's investor presentation, Sep 13, 2017

  1. Slide 1: Innovators in the development & commercialization of injectable collagenase

    &. e ‘a? S oan Innovators in the development & commercialization of: INJECTABLE COLLAGENASE o— "= : BioSpecifics September 2017

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995, All statements other than statements of historical fact, including statements regarding

  3. Slide 3: Company Overview

    Company Overview (NASDAQ: BSTC OOO Originator of collagenase based-therapies Positive clinical results for XIAFLEX reported in 12 indications to date Profitable biopharma company with lean corporate structure and stock buy-back program Receives revenues from XIAFLEX® milestones, royalties on net sal

  4. Slide 4: Pipeline

    XIAFLEX® Pipeline Dupuytren’s Contracture @endo Peyronie's Disease endo a commercial review Uterine Fibroids Cellulite endo aS Initiate Phase 3 trials by end of 2017 Adhesive Capsulitis endo ied vee cal Geers a Human tipoma enelel aS Beh ire eaiorminna Canine tipoma endo R= Lateral Hip Fat endo => E

  5. Slide 5: Marketed XIAFLEX Indications

    Marketed XIAFLEX Indications: Dupuytren’s Contracture & Peyronie’s Disease

  6. Slide 6: XIAFLEX 2Q 2017 Total Revenues

    XIAFLEX 2Q 2017 Total Revenues = Second quarter 2017 total revenues were $50.1M vs. $42.4M for second quarter 2016, an 18% growth

  7. Slide 7: XIAFLEX Future Growth Opportunities

    XIAFLEX Future Growth Opportunities Endo expects high-single to low-double-digit revenue growth for sales in 2017 Sizable opportunity for growth Of the patients diagnosed with Peyronie’s disease, 85-90% are untreated and for Dupuytren’s contracture 75-80% are untreated FUTURE GROWTH INITIATIVES: Bro

  8. Slide 8: Dupuytren's Contracture

    XIAFLEX® for Dupuytren’s Contracture Definition & Key Complications Deforming condition of the hand in which one or more fingers contracts toward the palm Limits range of motion and impairs quality of life Affects between 3-9% of adult Caucasians Pre-treatment: Post-treatment: Loam i Source: Endo In

  9. Slide 9: Peyronie's Disease

    XIAFLEX® for Peyronie’s Disease Definition & Key Complications Inelastic collagen causing penile curvature; penis can bend at 90° angle during erection in severe cases Associated with increased pain, painful erections, palpable plaque, penile deformity and erectile dysfunction Potential loss of self

  10. Slide 10: Pipeline Indications

    XIAFLEX® Pipeline Indications

  11. Slide 11: Uterine Fibroids

    XIAFLEX® for Uterine Fibroids Phase 1 Trial Ongoing Benign tumors in the reproductive tract that contain large amounts of collagen Definition & Key Cause pelvic discomfort and pain, decreased fertility, pregnancy Complications complications, increased rate of miscarriage, uterine bleeding, prolonged

  12. Slide 12: Uterine Fibroids

    XIAFLEX® for Uterine Fibroids Phase 1 Trial Design Open-label dose escalation Phase 1 study in 15 female subjects treated prior to hysterectomy at the Department of Gynecology & Obstetrics at Johns Hopkins University 3 subjects injected with saline and 12 to receive XIAFLEX Primary endpoint: Assess

  13. Slide 13: Potential Advantages of XIAFLEX

    Potential Advantages of XIAFLEX® Injection vs. Major Surgery Shorter, Easier Process 5-10 minutes vs. 2-4 hours for hysterectomy and myomectomy and 1-2 hours for uterine artery embolization No intubation Sedation vs. anesthesia for surgery Limited Recovery Time “Lost work” costs of $4,500-$30,000 pe

  14. Slide 14: Cellulite

    XIAFLEX® for Cellulite Phase 3 Trials to Initiate By End of 2017 OVERVIEW Skin dimpling as a result of collagen fibrous septae, occurring mainly on the buttocks, lower limbs, and abdomen Highly Statistically Significant Affects ~85-98% of post-pubertal Positive Results from Phase females 2b Study aa

  15. Slide 15: Cellulite

    XIAFLEX® for Cellulite Highly Statistically Significant Top-line Data from Phase 2b Study 375 women with moderate or severe cellulite (18+ years) Up to 3 treatment sessions of 0.84 mg/session or placebo (12 injections per session) with each treatment session occurring 21 days apart Primary endpoint

  16. Slide 16: Adhesive Capsulitis

    XIAFLEX® for Adhesive Capsulitis Potential to be Only FDA Approved Nonsurgical Therapy Inflammation and thickening of shoulder capsule due to collagen Limits range of motion of shoulder Common available treatment options are often painful and can require anesthesia Long-term intensive physical thera

  17. Slide 17: Phase 2b Study Results of XIAFLEX in Adhesive Capsulitis

    Phase 2b Study Results of XIAFLEX® in Adhesive Capsulitis/Frozen Shoulder Syndrome Phase 2a Results 321 patient double-blind, placebo-controlled study evaluating safety and efficacy in Stage 2 (frozen stage) unilateral idiopathic frozen shoulder a Primary endpoint: change in degrees from baseline to

  18. Slide 18: Human Lipomas

    XIAFLEX® for Human Lipomas Potential to be Only FDA-Approved Pharmaceutical Therapy U.S. Market Opportunity Phase 2 Trial Design Encapsulated deposits of benign fat, often detected as bulges under the skin No FDA-approved pharmaceutical therapies available Offers an alternative to patients that may

  19. Slide 19: Positive Top-Line Phase Study Results

    Positive Top-Line Phase 2 Study Results Single 0.58 mg Injection of XIAFLEX Primary endpoint: 81.3% reduction in visible surface area for XIAFLEX vs. 2.1% increase for placebo; 83.4% difference in favor of XIAFLEX (p<0.0001) 89.5% responder rate (showed a 250% decrease in lipoma visible surface area

  20. Slide 20: Lateral Hip Fat

    XIAFLEX® for Lateral Hip Fat Definition & Complications Similar prevalence to cellulite Fat accumulation is common among woman particularly as they age Often very difficult to improve its appearance through exercise and diet alone Patients frequently avoid exercise and are unable to restrict their c

  21. Slide 21: Plantar Fibromatosis

    XIAFLEX® for Plantar Fibromatosis Definition & Complications ~200,000 patients in the U.S. Pain and disability caused by the thickening of the feet's deep connective tissue Formation of nodules or cords along tendons of the foot Patients often have Dupuytren’s disease, Peyronie’s disease and adhesiv

  22. Slide 22: Additional Promising Unlicensed Indications

    Additional Promising Unlicensed Indications Capsular Contracture, Breast Hypertrophic Scars & Keloids Dercum’s Disease Knee Arthrofibrosis Urethral Strictures Source: Endo International ple Post-surgical complication that can deform the breast and cause pain Scars that form on the skin at site of in

  23. Slide 23: Endo Partnership for Development and Commercialization of XIAFLEX

    Endo Partnership for Development and Commercialization of XIAFLEX >$120M Received $120M received in licensing, sublicensing, milestone, as of June 30, 2017 COGS, and royalty payments as of June 30, 2017 Low double digit royalties as % of net sales Future Payments Additional mark-up on COGS for U.S.

  24. Slide 24: Strong IP Portfolio

    Strong IP Portfolio Dupuytren’s Contracture Biologic Exclusivity until 2022 Drug product composition patent until 2028 Peyronie’s Disease Orphan Drug protection in U.S. until 2020 Drug product composition patent until 2028 Uterine Fibroids Method of use patent until 2034 Patents and Patent Applicati

  25. Slide 25: Consistently Profitable Annually

    Consistently Profitable Annually Financial Highlights (unaudited) For the six months ended 06/30/2017 06/30/2016 Cash and equivalents, and investments $58,542,247 $45,836,222 Income Statement Revenues $14,266,135 $12,748,147 Other income 268,733 151,224 Costs and expenses (5,333,512) (4,759,393) Pro

  26. Slide 26: Anticipated Upcoming Pipeline Milestones

    Anticipated Upcoming Pipeline Milestones Initiate Phase 3 clinical trials by end of 2017 Publication of full Phase 2b data Cellulite a O Commercial review of additional indications and priority programs Other Indications “ ongoing BIOSPECIFI Serious Medical Conditions Uterine Fibroids Enrollment ong

  27. Slide 27: —_ a EEE

    —_ a EEE é ‘a? = —_ Innovators in the development & commercialization of INJECTABLE « COLLAGENASE om ‘ion wrx BioSpecifics September 2017

BioSpecifics Technologies — Investor Presentation (September 2017) on 6ix